ACM
BMRN icon

Acrisure Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Acrisure Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,364
Closed -$230K – 35
2023
Q1 		$230K Buy
+2,364
New +$245K 0.23% 205

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Acrisure Capital Management's BMRN Position: Q2 2023 in Review

Acrisure Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2023, closing a stake of 2,364 shares — an estimated $230K sold.

Acrisure Capital Management first reported a position in BMRN in Q1 2023 and held it in 1 quarter. The position peaked at $230K in Q1 2023. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

  • Acrisure Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Acrisure Capital Management sold 2,364 BioMarin Pharmaceuticals shares in Q2 2023, an estimated $230K.
  • Acrisure Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Acrisure Capital Management's BioMarin Pharmaceuticals position peaked at $230K in Q1 2023.
  • 558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on Acrisure Capital Management's 13F filing for Q2 2023.